EPO-TRAUMA Trial

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients: a multi-centre, stratified, double-blind, randomised, placebo-controlled trial. (The EPO-TRAUMA trial)

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients

Sites32
Patients851

Committee
Contacts
Progress

Study Progress

Country	Recruited
Australia	470
New Zealand	166
Finland	71
Switzerland	59
Saudi Arabia	43
Ireland	31
Slovenia	11
Total	851